|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0023175,
umls-concept:C0072780,
umls-concept:C0205198,
umls-concept:C0205531,
umls-concept:C0226896,
umls-concept:C0243076,
umls-concept:C0387687,
umls-concept:C0441655,
umls-concept:C0442027,
umls-concept:C0935763,
umls-concept:C1527415,
umls-concept:C2698650
|
|
pubmed:issue |
20
|
|
pubmed:dateCreated |
2001-10-9
|
|
pubmed:abstractText |
Investigations of the structure-activity relationships of 1,3,4-trisubstituted pyrrolidine human CCR5 receptor antagonists afforded orally bioavailable compounds with the ability to inhibit HIV replication in vitro.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:BudtzP EPE,
pubmed-author:CarellaAA,
pubmed-author:CarverGG,
pubmed-author:DanzeisenRR,
pubmed-author:DeMartinoJ AJA,
pubmed-author:EminaMM,
pubmed-author:FinkeP EPE,
pubmed-author:GouldS LSL,
pubmed-author:HaleJ JJJ,
pubmed-author:HazudaDD,
pubmed-author:HolmesKK,
pubmed-author:HolsonE BEB,
pubmed-author:KesslerJJ,
pubmed-author:LinebergerJJ,
pubmed-author:MacCossMM,
pubmed-author:MalkowitzLL,
pubmed-author:MillerMM,
pubmed-author:MillsS GSG,
pubmed-author:OatesBB,
pubmed-author:SchleifW AWA,
pubmed-author:SicilianoSS,
pubmed-author:SpringerM SMS
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
22
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2741-5
|
|
pubmed:dateRevised |
2005-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11591514-Administration, Oral,
pubmed-meshheading:11591514-Animals,
pubmed-meshheading:11591514-Anti-HIV Agents,
pubmed-meshheading:11591514-Biological Availability,
pubmed-meshheading:11591514-CHO Cells,
pubmed-meshheading:11591514-Cricetinae,
pubmed-meshheading:11591514-HIV,
pubmed-meshheading:11591514-HeLa Cells,
pubmed-meshheading:11591514-Humans,
pubmed-meshheading:11591514-Microbial Sensitivity Tests,
pubmed-meshheading:11591514-Pyrrolidines,
pubmed-meshheading:11591514-Receptors, CCR5,
pubmed-meshheading:11591514-Structure-Activity Relationship
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity.
|
|
pubmed:affiliation |
Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA. jeffrey_hale@merck.com
|
|
pubmed:publicationType |
Journal Article
|
